Exciting update from our portfolio company @Bicara Therapeutics at @ESMO !
Yesterday, our Chief Medical Officer David Raben, M.D., and team presented updated interim data from our ongoing Phase 1/1b study of BCA101, our first-in-class bifunctional EGFR/TGF-β antibody, in those with HPV-negative recurrent/metastatic head and neck squamous cell carcinoma at the European Society for Medical Oncology's #ESMO23 Congress. Read more in the release below.
